AbbVie terminates Alector's AL003/CD33 Alzheimer's collaboration

Alector, Inc.

AbbVie provided written notice on June 30, 2022 terminating the CD33 (AL003) program.
Alector and AbbVie continue to advance the AL002 (TREM2) program under the existing agreement.
No financial or milestone termination payments disclosed in the filing.

item 8.01

Alector, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-189463

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.